Literature DB >> 29605689

HLA-G mediated immune regulation is impaired by a single amino acid exchange in the alpha 2 domain.

Alexander A Celik1, Gwendolin S Simper1, Trevor Huyton2, Rainer Blasczyk1, Christina Bade-Döding3.   

Abstract

The trade-off from HLA class I expression to HLA-G expression support the immune evasion of malignant cells. The essential role of the virtually invariant HLA-G in immune tolerance, tumor immunology and its expression frequency in immune privileged tissues is known; however the specific importance of allelic subtypes in immune responses is still not well understood. HLA-G∗01:01, ∗01:03 and ∗01:04 are the most prevalent allelic variants differing at residues 31 and 110, respectively. In cytotoxicity assays applying K562 cells transduced with the HLA-G variants as targets and NK cells as effectors the differential protective potential of HLA-G variants was analyzed. Their peptide profiles were determined utilizing soluble HLA technology. An increased protective potential of HLA-G∗01:04 could be observed. All variants exhibit a unique peptide repertoire with marginal overlap, while G∗01:04 differs in its peptide anchor profile substantially. The functional differences between HLA-G subtypes could be explained by the constraint of the bound peptides, modifying the pHLA-G accessible surface. For the first time a contribution of amino acid alterations within the HLA-G heavy chain for peptide selection and NK cell recognition could be observed. These results will be a step towards understanding immune tolerance and will guide towards personalized immune therapeutic strategies.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  HLA-G; NK cells; Peptides; Tolerance

Mesh:

Substances:

Year:  2018        PMID: 29605689     DOI: 10.1016/j.humimm.2018.03.010

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  16 in total

1.  NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain.

Authors:  Gia-Gia T Hò; Alexander A Celik; Trevor Huyton; Wiebke Hiemisch; Rainer Blasczyk; Gwendolin S Simper; Christina Bade-Doeding
Journal:  Int J Mol Sci       Date:  2020-06-19       Impact factor: 5.923

2.  Clinical Significance of Potential Unidentified HLA-G Isoforms Without α1 Domain but Containing Intron 4 in Colorectal Cancer Patients.

Authors:  Aifen Lin; Xia Zhang; Rui-Li Zhang; Jian-Gang Zhang; Wen-Jun Zhou; Wei-Hua Yan
Journal:  Front Oncol       Date:  2018-09-04       Impact factor: 6.244

3.  HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues.

Authors:  Gia-Gia T Hò; Funmilola J Heinen; Trevor Huyton; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2019-04-02       Impact factor: 2.846

4.  The microstructure in the placenta is influenced by the functional diversity of HLA-G allelic variants.

Authors:  F Stieglitz; A A Celik; C von Kaisenberg; M A Camps; R Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2019-06-27       Impact factor: 2.846

5.  HLA-H: Transcriptional Activity and HLA-E Mobilization.

Authors:  François Jordier; Delphine Gras; Maria De Grandis; Xavier-Benoît D'Journo; Pascal-Alexandre Thomas; Pascal Chanez; Christophe Picard; Jacques Chiaroni; Julien Paganini; Julie Di Cristofaro
Journal:  Front Immunol       Date:  2020-01-17       Impact factor: 7.561

Review 6.  HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation.

Authors:  Burcu Duygu; Timo I Olieslagers; Mathijs Groeneweg; Christina E M Voorter; Lotte Wieten
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 7.561

7.  HLA-G whole gene amplification reveals linkage disequilibrium between the HLA-G 3'UTR and coding sequence.

Authors:  Jos J M Drabbels; Robert Welleweerd; Inge van Rooy; Guro M Johnsen; Anne Cathrine Staff; Geert W Haasnoot; Nienke Westerink; Frans H J Claas; Erik Rozemuller; Michael Eikmans
Journal:  HLA       Date:  2020-05-17       Impact factor: 4.513

8.  HLA-F Allele-Specific Peptide Restriction Represents an Exceptional Proteomic Footprint.

Authors:  Gia-Gia T Hò; Funmilola J Heinen; Rainer Blasczyk; Andreas Pich; Christina Bade-Doeding
Journal:  Int J Mol Sci       Date:  2019-11-08       Impact factor: 5.923

Review 9.  The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

Authors:  Jiji V D Attia; Charlotte E Dessens; Ricky van de Water; Ruben D Houvast; Peter J K Kuppen; Daniëlle Krijgsman
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

Review 10.  HLA-G/ILTs Targeted Solid Cancer Immunotherapy: Opportunities and Challenges.

Authors:  Aifen Lin; Wei-Hua Yan
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.